Clearside Biomedical, Inc. to Present at International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical Meeting
Alpharetta, GA (July 9, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced Glenn Noronha, PhD, executive vice president of Research and Development of Clearside, will present at the 2015 International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical meeting in Berlin, Germany on Friday, July 10. Dr. Noronha’s presentation “Using suprachoroidal administration as an approach to treat noninfectious uveitis – from concept through clinical data” will be part of the afternoon Drug Delivery session.
“Unlike intravitreal (IVT) delivery of drug therapy where drugs are dispersed throughout the eye, administration to the suprachoroidal space (SCS) enables drug to be administered directly to the retina and choroid, which are the most common sites where back-of-the-eye diseases originate or manifest,” said Dr. Noronha. “Based on data from Clearside’s completed Phase 1/2 study in non-infectious uveitis patients, we believe that SCS administration of steroid in the eye using our proprietary microinjector will provide robust differentiating efficacy while avoiding or reducing some of the side effects that are commonly associated with steroid usage.”
About Uveitis
Uveitis is one of the most frequent causes of blindness in the developed world. Based on prevalence data published in the journal Ophthalmology in 2004 and United States census data for 2010, it is estimated approximately 350,000 individuals in the United States suffer from some form of uveitis. Typically diagnosed in individuals between the ages of 20 and 50, uveitis can occur in one or both eyes and accounts for approximately 10% of cases of blindness in the United States, according to a study published in Journal of Ophthalmology. Uveitis can be either infectious or non-infectious. Non-infectious uveitis accounts for approximately 80% of all uveitis cases. Macular edema related to uveitis is the predominant cause of blindness or visual impairment among patients with uveitis, accounting for approximately 30% of cases of blindness in uveitis patients. Because uveitis can become chronic or recurrent if not adequately treated, some patients may become refractory, or unresponsive, to treatment, leading to irreversible blindness.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema. Visit www.clearsidebio.com for more information.
Contact
Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
charlie.deignan@clearsidebio.com